- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00466882
Use of the INAMED LAPBAND System to Reduce BMI's in Obese Renal Failure Patients
Issues Related to the Use of the INAMED LAPBAND SYSTEM to Reduce BMI's in Obese Renal Failure Patients Needing Renal Transplantation: A Pilot Study
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
The concern of transplant surgeons is that obese patients with high BMI's are more likely to experience post-transplantation complications than age-matched recipients [1]. Nevertheless, the Summa transplant list contains numerous patients with renal failure that have BMI's above 35. These patients are not considered to be "active" transplant candidates because of their obesity and are not eligible to receive a kidney transplant. Dr. Lal counsels these patients that they must lose weight in order to be considered active candidates for transplantation.
Weight loss for obese patients in renal failure is difficult. These patients must undergo hemodialysis three times weekly. Most of these patients do not, or physically cannot, engage in exercise activities. Many of these patients are burdened psychologically, and further behavioral responsibilities related to weight loss may overstress them. Repetitive diets or behavioral therapy in morbidly obese patients prior to transplantation have had disappointing results [2]. Likewise, pharmacological management of obesity in these patients is largely unsuccessful. Noradrenergic appetite suppressants must be restricted because of stimulatory side-effects. Serotonergic agents have cardiovascular and pulmonary complications. Thermogenic agents are minimally effective [2].
The INAMED LAPBAND SYSTEM is an FDA-approved, surgically-placed device marketed to facilitate weight reduction in obese individuals. The LAPBAND is positioned laparoscopically around the stomach and requires an overnight hospitalization and an upper GI swallow the next morning. The device can be gradually adjusted to increase stomach constriction by the physician in an office setting so that the patient loses approximately 1-2 pounds per week over two years. These adjustments are performed on average 4-5 times during the first year and twice during the second year.
The purpose of this pilot study is to assess the utility of the LAPBAND in facilitating weight loss in obese renal failure patients awaiting transplantation and to document issues related to its use in these patients. The hope is that the LAPBAND will facilitate enough weight loss to reduce the patient's BMI to 35 or below after placement of the LAPBAND. If the patient reaches the intended goal of BMI of 35, they will be placed on the active renal transplant list and will be eligible for transplantation.
A secondary goal of this research is to follow those patients who successfully reach BMI's of 35 or less who are subsequently transplanted to determine any untoward effects of the LAPBAND upon transplantation success
Studietype
Contacten en locaties
Studie Locaties
-
-
Ohio
-
Akron, Ohio, Verenigde Staten, 44304
- Summa Health System
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- 18 or older
- Hemodialysis patient with BMI between 36 and 42
Exclusion Criteria:
- Patients undergoing peritoneal dialysis
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Ander
- Tijdsperspectieven: Retrospectief
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
---|---|
Inamed Lap-Band System
The LAPBAND is positioned laparoscopically around the stomach and requires an overnight hospitalization and an upper GI swallow the next morning.
The device can be gradually adjusted to increase stomach constriction by the physician in an office setting so that the patient loses approximately 1-2 pounds per week over two years.
|
Patient's will be seen in the physician's office one week post surgery and once a month thereafter.
The device can be gradually adjusted by the insertion of a needle into the port and saline is added or removed to inflate or deflate the LAPBAND.
This can be conducted in the physician's office setting to enable the patient to lose 1-2 pounds per week over two years.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Weight Loss
Tijdsspanne: 2 years
|
Assess weight loss after surgery
|
2 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Transplantation Success
Tijdsspanne: 2 years
|
Assess possible effects of weight loss surgery on transplantation success
|
2 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: John Zografakis, MD, Summa Health System
- Hoofdonderzoeker: Tanamay Lal, MD, Summa Health System
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- INAMED
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Inamed Lap-Band System
-
NYU Langone HealthHope FoundationVoltooidObesitas | DMVerenigde Staten
-
Jeffrey L Zitsman, MDVoltooidObstructief slaapapneusyndroom | Metaboolsyndroom | Insuline-resistentie | Morbide obesitas | Niet-alcoholische leververvettingVerenigde Staten
-
Apollo Endosurgery, Inc.VoltooidObesitasVerenigd Koninkrijk, Australië, Verenigde Staten, Italië, Canada, België
-
Apollo Endosurgery, Inc.Voltooid
-
Apollo Endosurgery, Inc.VoltooidMorbide obesitasVerenigde Staten
-
InamedMassachusetts Veterans Epidemiology Research and Information CenterOnbekendOntsteking | Lever functie | Glykemische controle | Epworth-slaperigheidsschaal | IJzer- en botomzet | SF-36 | IW-QOL Lite HRQoL
-
University of Texas Southwestern Medical CenterBeëindigd
-
University of California, IrvineVoltooidMorbide obesitasVerenigde Staten
-
Tenet Healthcare CorporationOnbekend
-
IntraPace, IncOnbekendObesitas | Morbide obesitasSpanje, Duitsland, Frankrijk, Italië, Zwitserland, Verenigd Koninkrijk